Role of estrogen receptors in pro-oxidative and anti-oxidative actions of estrogens: A perspective

Biochimica et Biophysica Acta - General Subjects

Volumn 1800, Issue 10, 2010, Pages 1127-1135

  Kumar, Sukhdeep ^a   Lata, Kusum ^a   Mukhopadhyay, Srirupa ^a   Mukherjee, Tapan K ^a  

^a INDIAN INSTITUTE OF SCIENCE EDUCATION AND RESEARCH MOHALI   (India)

Author keywords

Anti oxidative action; Estrogen receptor related receptors; Estrogen receptors; Estrogens; Pro oxidative action

Indexed keywords

17 EPIESTRIOL; 2 HYDROXYESTRADIOL; 2,3 ESTRADIOLQUINONE; 3,4 ESTRADIOLQUINONE; 4 HYDROXYESTRADIOL; 4 HYDROXYESTRONE; CATECHOL ESTROGEN; ESTRADIOL; ESTRADIOL DERIVATIVE; ESTRIOL; ESTROGEN; ESTROGEN DERIVATIVE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTRONE; ETHINYLESTRADIOL; FULVESTRANT; GENISTEIN; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; NITRIC OXIDE; PHENOL; PHYTOESTROGEN; PROGESTERONE; QUINONE DERIVATIVE; RALOXIFENE; REACTIVE OXYGEN METABOLITE; STEROID HORMONE; TAMOXIFEN; THIOREDOXIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTIOXIDANT; ESTROGEN RECEPTOR; ORAL CONTRACEPTIVE AGENT; OXIDIZING AGENT;

ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; BREAST CANCER; CARDIOVASCULAR DISEASE; CELL TYPE; CEREBROVASCULAR ACCIDENT; DEGENERATIVE DISEASE; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG WITHDRAWAL; ESTROGEN METABOLISM; HEART PROTECTION; HORMONE ACTION; HORMONE RESPONSE; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; MENOPAUSAL SYNDROME; MITOCHONDRIAL ENERGY TRANSFER; MITOCHONDRIAL RESPIRATION; MULTIINFARCT DEMENTIA; NERVE CELL; NEUROPROTECTION; NONHUMAN; ORAL CONTRACEPTION; OXIDATION REDUCTION REACTION; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; STRUCTURE ACTIVITY RELATION; ANIMAL; ANTIBODY SPECIFICITY; DRUG EFFECTS; ESTROGEN THERAPY; FEMALE; MALE; METABOLISM; MITOCHONDRION; NEOPLASM; PREMENOPAUSE;

ANIMALS; ANTIOXIDANTS; CARDIOVASCULAR DISEASES; CONTRACEPTIVES, ORAL, HORMONAL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MALE; MITOCHONDRIA; NEOPLASMS; NEURODEGENERATIVE DISEASES; NEURONS; ORGAN SPECIFICITY; OXIDANTS; OXIDATION-REDUCTION; PREMENOPAUSE; RECEPTORS, ESTROGEN;

EID: 77956180061     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagen.2010.04.011     Document Type: Review

References (113)

1. Ginsburg E.S., Gao X., Shea B.F., Barbieri R.L. Half-life of estradiol in postmenopausal women. Gynecol. Obstet. Invest. 1998, 45:45-48.
2. Nilsson S., Makela S., Treuter E., et al. Mechanisms of estrogen action. Physiol. Rev. 2001, 81:1535-1565.
3. Palacios S. Current perspectives on the benefits of HRT in menopausal women. Maturitas 1999, 33(Suppl 1):S1-S13.
4. Behl C., Skutella T., Lezoualc H.F., Post A., Widmann M., Newton C.J., Holsboer F. Neuroprotection against oxidative stress by estrogens: structure-activity relationship. Mol. Pharmacol. 1999, 51:535-541.
5. Nilsen J. Estradiol and neurodegenerative oxidative stress. Front. Neuroendocrinol. 2008, 29:463-475.
6. Rossow J.E., Anderson G.L., Prentice R.L., LaCroix Az., Kooperberg C., Stefanick M.L., Jackson R.D., Beresford S.A., Howard B.V., Johnson K.C., Kotchen J.M., Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principle results from the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321-333.
7. Shumaker S.A., Legault C., Rapp S.R., Thal L., Wallace R.B., Ockene J.K., Hendrix S.L., Jones B.N., Assaf A.R., Jackson R.D., Kotchen J.M., Wassertheil-Smoller S., Wactawski-Wende J. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women, The Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003, 289:2651-2662.
8. Brass L.M. Estrogens and stroke: use of oral contraceptives and postmenopausal use of estrogen: current recommendations. Curr. Treat. Options Neurol. 2004, 6:459-467.
9. Ravdin P.M., Cronin K.A., Howlader N., Berg C.D., Chlebowski R.T., Feuer E.J., Edwards B.K., Berry D.A. The decrease in breast-cancer incidence in 2003 in the United States. N. Engl. J. Med. 2007, 356:1670-1674.
10. Key T., Appleby P., Barnes I., Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J. Natl. Cancer Inst. 2002, 94:606-616.
11. Felty Q., Singh K.P., Roy D. Estrogen induced G1/S transition of G(0)-arrested estrogen dependent breast cancer cells is regulated by mitochondrial oxidant signaling. Oncogene 2005, 24:4883-4893.
12. Yager J.D., Davidson N.E. Estrogen carcinogenesis in breast cancer. N. Engl. J. Med. 2006, 354:270-282.
13. Bolton J.L., Thatcher G.R. Potential mechanisms of estrogen quinone carcinogenesis. Chem. Res. Toxicol. 2008, 21:93-101.
14. Jensen E.V. On the mechanism of estrogen action. Perspect. Biol. Med. 1962, 6:47-59.
15. Green S., Walter P., Kumar V. Human oestrogen receptor cDNA: sequence, expression and homology to v-erbA. Nature 1986, 320:134-139.
16. Kuiper G., Enmark E., Pelto-Huikko M., Nilsson S., Gustafsson J.A. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:5925-5930.
17. Tremblay G.B., Tremblay A., Copeland N.G., Gilbert D.J., Jenkins N.A., Labrie F., Giguere V. Cloning, chromosomal localization and functional analysis of the murine estrogen receptor beta. Mol. Endocrinol. 1997, 11:353-365.
18. Mosselman S., Polman J., Dijkema R. ERβ: identification and characterization of a novel human estrogen receptor. FEBS Lett. 1996, 392:49-53.
19. Leung Y.K., Mak P., Hassan S., Ho S.M. Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:13162-13167.
20. Hawkins M.B., Thornton J.W., Crews D., Skipper J.K., Dotte A., Thomas P. Identification of a third distinct estrogen receptor and reclassification of estrogen receptors in teleosts. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:10751-10756.
21. Shughrue P.J., Lane M.V., Merchenthaler I. Comparative distribution of estrogen receptor alpha and beta mRNA in the rat central nervous system. J. Comp. Neurol. 1997, 388:507-525.
22. Shughrue P.J., Scrimo P.J., Merchenthaler I. Evidences for the colocalization of estrogen receptor beta mRNA and estrogen receptor alpha immunoreactivity in neurons of the rat forebrain. Endocrinology 1998, 139:5267-5270.
23. Shughrue P.J., Scrimo P.J., Merchenthaler I. Estrogen binding and estrogen receptor characterization (ER-alpha and ER-beta) in the cholinergic neurons of the rat basal forebrain. Neuroscience 2000, 96:41-49.
24. Zhang J.Q., Cai W.Q., Zhou D.S., Su B.Y. Distribution and differences of estrogen receptor beta immunoreactivity in the brain of adult male and female rats. Brain Res. 2002, 935:73-80.
25. Milner T.A., Ayoola K., Drake C.T., Herrick S.P., Tabori N.E., McEwen B.S. Ultrastructural localization of estrogen receptor beta immunoreactivity in the rat hippocampal formation. J. Comp. Neurol. 2005, 491:81-95.
26. Toran-Allerand C.D. Minireview: a plethora of estrogen receptors in the brain: where will it end?. Endocrinology 2004, 145:1069-1074.
27. Kuiper G.G., Carlson B., Grandien K., Enmark E., Haggblad J., Nilsson S., Gustaffson J.A. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen alpha and beta. Endocrinology 1997, 138:863-870.
28. Mukherjee T.K., Nathan L., Dinh H., Reddy S.T., Chaudhuri G. 17-Epiestriol, an estrogen metabolite, is more potent than estradiol in inhibiting vascular cell adhesion molecule 1 (VCAM-1) mRNA expression. J. Biol. Chem. 2003, 278:11746-11752.
29. Perez E.J., Cai Y.C., Covey D.F., Simpkins J.W. Neuroprotective effects of estratriene analogs: structure-activity relationship and molecular optimization. Drug Dev. Res. 2006, 66:78-92.
30. Ammeller T., Legrand P., Marsaud V., Renoir J.M. Drug delivery systems for estrogenic hormones and antagonists: the need for selective targeting in estradiol dependent cancers. J. Steroid Biochem. Mol. Biol. 2004, 92:1-18.
31. Zhao L., O'Neill K., Brinton R.D. Selective estrogen receptor modulators (SERMs) for the brain: current status and remaining challenges for developing NeuroSERMs. Brain Res. Rev. 2005, 49:472-493.
32. Rollerova E., Urbancikova M. Intracellular estrogen receptors, their characterization and function (review). Endocr. Regul. 2000, 34:203-218.
33. O'Lone R., Frith M.C., Karlsson E.K., Hansen U. Genomic targets of nuclear estrogen receptors. Mol. Endocrinol. 2004, 18:1859-1875.
34. Cheskis B.J., Greger J.G., Nagpal S., Freedman L.P. Signaling by estrogens. J. Cell. Physiol. 2007, 321:610-617.
35. Stice J.P., Knowlton A.A. Estrogen, NFκB, and the heat shock response. Mol. Med. 2008, 14:517-527.
36. Kushner P.J., Agard D.A., Greene G.L., Scanlan T.S., Shiau A.K., Uht R.M., Webb P. Estrogen receptor pathways to AP-1. J. Steroid Biochem. Mol. Biol. 2000, 74:311-317.
37. Saville B., Wormke M., Wang F., Nguyen T., Enmark E., Kuiper G., Gustafsson J.A., Safe S. Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (SP1) promoter elements. J. Biol. Chem. 2000, 275:5379-5387.
38. Briegel K., Lim K.C., Plank C., Beng H., Engel J.D., Zenke M. Ectopic expression of a conditional GATA 2/estrogen receptor chimera arrests erythroid differentiation in a hormone dependent manner. Genes Dev. 1993, 7:1097-1109.
39. Behl C. Estrogen as a neuroprotective hormone. Nat. Rev. Neurosci. 2002, 3:433-442.
40. Pietras R.J., Szego C.M. Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells. Nature 1977, 265:69-72.
41. Levin E.R. Cell localization, physiology and nongenomic actions of estrogen receptors. J. Appl. Physiol. 2001, 91:1860-1867.
42. Berthois Y., Pourreau-Schneider N., Gandilhon P., Mittre H., Tubiana N., Martin P.M. Estradiol membrane binding sites on human breast cancer cell lines. Use of fluorescent estradiol conjugate to demonstrate plasma membrane binding systems. J. Steroid Biochem. 1986, 25:963-972.
43. Kampa M., Nifli A.P., Charalampopoulos I., Alexaki V.I., Theodoropoulos P.A., Stathopoulos E.N. Opposing effects of estradiol and testosterone membrane binding sites on T47D breast cancer cell apoptosis. Exp. Cell Res. 2005, 307:41-51.
44. Razandi M., Pedram A., Greene G.L., Levin E.R. Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells. Mol. Cell. Endocrinol. 1999, 13:307-319.
45. Pappas T.C., Gametchu B., Watson C.S. Membrane estrogen receptors identified by multiple antibody labeling and impeded-ligand binding. FASEB J. 1995, 9:404-410.
46. Kim K.H., Moriarty K., Bender J.R. Vascular cell signaling by membrane estrogen receptors. Steroids 2008, 73(2008):864-869.
47. Zheng J., Ramirez V.D. Demonstration of membrane estrogen binding proteins in rat brain by ligand blotting. J. Steroid Biochem. Mol. Biol. 1997, 62:327-336.
48. Razandi M., Oh P., Pedram A., Schnitzer J., Levin E.R. ERs associate with and regulate the production of cavealin: implication for signaling and cellular actions. Mol. Endocrinol. 2002, 16:100-115.
49. Boulware M.I., Kordasiewicz H., Mermelstein P.G. Caveolin proteins are essential for distinct effects of membrane estrogen receptors in neurons. J. Neurosci. 2007, 27:9941-9950.
50. Acconcia F., Ascenzi P., Bocedi A., Spisni E., Tomasi V., Tretalance A. Palmitoylation-dependent estrogen receptor alpha membrane localization: regulation by 17-beta-estradiol. Mol. Biol. Cell 2005, 16:231-237.
51. Longo M., Brama M., Marino M., Bernardini S., Korach K.S., Westel W.C. Interaction of estrogen receptor alpha with protein kinase C alpha and c-Src in osteoblast during differentiation. Bone 2004, 34:100-111.
52. Lu Q., Pallas D.C., Surks H.K., Baur W.E., Mendelsohn M.E., Karas R.H. Striatin assembles a membrane signaling complex necessary for rapid, nongenomic activation of endothelial NO synthases by estrogen receptor alpha. PNAS (USA) 2004, 101:17126-17131.
53. Barletta F., Wong C.W., McNally C., Komm B.S., Katzenellenbogen B., Cheskis B.J. Characterization of the interactions of estrogen receptor and MNAR in the activation of cork. Mol. Endocrinol. 2004, 18:1096-1108.
54. Vasudevan N., Pfaff D.W. Non-genomic actions of estrogens and their interaction with genomic actions in the brain. Front. Neuroendocrinol. 2008, 29:238-257.
55. Raz L., Khan M.M., Mahesh V.B., Vadlamudi R.K. Rapid estrogen signaling in the brain. Neurosignals 2008, 16:140-153.
56. Singh M., Setalo G., Guan X., Frail D.E., Toran-Allerand C.D. Estrogen induced activation of mitogen activated protein kinase cascade in the cerebral cortex of estrogen receptor alpha knock out mice. J. Neurosci. 2000, 20:1694-1700.
57. Abraham J.M., Todman M.G., Koeach K.S., Herbison A.E. Critical in vivo roles for classical estrogen receptors in rapid estrogen actions on intracellular signaling in mouse brain. Endocrinology 2004, 145:3055-3061.
58. Dominguez-Salazar E., Shetty S., Rissman E.F. Rapid neural FOS responses to estradiol in Eralpha Erbeta knock out mice. J. Neuroendocrinol. 2006, 18:195-202.
59. Rai D., Frolova A., Frasor J., Carpenter A.E., Katzenellenbogen S.Benita Distinctive actions of membrane-targeted versus nuclear localized estrogen receptors in breast cancer cells. Molecular Endocrinology 2005, 19:1606-1617.
60. Vasudevan N., Kow L.M., Pfaff D. Integration of steroid hormone initiated membrane action to genomic function in the brain. Steroids 2005, 70:388-396.
61. Hammes S.R., Levin E.R. Extranuclear steroid receptors: nature and actions. Endocr. Rev. 2007, 28:726-741.
62. Wang X., Simkins J.W., Dykens J.A., Cammarata P.R. Oxidative damage to human lens epithelial cells in culture: estrogen protection of mitochondrial potential, ATP and cell viability. Invest. Ophthalmol. Vis. Sci. 2003, 44:2067-2075.
63. Stirone C., Duckles S.P., Krause D.N., Procaccio V. Estrogen increases mitochondrial efficiency and reduces oxidative stress in cerebral blood vessels. Mol. Pharmacol. 2005, 68(4):959-965.
64. Fuqua S.A., Cui Y. Estrogen and progesterone receptor isoforms: clinical significance in breast cancer. Breast Cancer Res. Treat. 2004, 87(Suppl 1):S3-S10.
65. Chen J.Q., Delannoy M., Cooke C., Yager J.D. Mitochondrial localization of ERα and ERβ in human MCF-7 cells. Am. J. Physiol. Endocrinol. Metab. 2004, 28:1011-1022.
66. Morkuniene R., Jekabsona A., Borutaite V. Estrogen prevent calcium-induced release of cytochrome c from heart mitochondria. FEBS Lett. 2002, 521:53-56.
67. Forster C., Kietr S., Hultenby K., Warner M., Gustaffson J.A. Characterization of the ERβ/mouse heart. PNAS (USA) 2004, 101:14234-14239.
68. Pedram A., Razandi M., Wallace D.C., Levin E.R. Functional estrogen receptors in the mitochondria of breast cancer cells. Mol. Biol. Cell 2006, 17:2125-2137.
69. Simpkins J.W., Yi K.D., Dykens J. Mitochondrial mechanisms of 774 estrogen neuroprotection. Biochim. Biophys. Acta 2010, 1800:1113-1120.
70. Nilsen J., Chen S., Irwin R.W., Iwamoto S., Brinton R.D. Estrogen protects neuronal cells from amyloid beta-induced apoptosis via regulation of mitochondria proteins and function. BMC Neurosci. 2006, 7:74-84.
71. Wang L.H., Yang K.Y., Zhang X., Mihalic K., Fan Y.X., Xiao W., Howard O.M., Appela E., Maynard A.T., Farrar W.L. Suppression of breast cancer by chemical modulation of vulnerable zinc fingers in estrogen receptor. Nat. Med. 2004, 10:40-47.
72. Atsriku C., Scott G.K., Benz C.C., Baldwin M.A. Reactivity of zinc finger cysteines: chemical modifications with labile zinc fingers in estrogen receptors. J. Am. Soc. Mass Spectrom. 2005, 16:2017-2026.
73. Staniek K., Gille L., Kozlov A.V., Nohl H. Mitochondrial superoxide radical formation is controlled by electron bifurcation to the high and low potential pathways. Free Radic. Res. 2002, 36:381-387.
74. Frey R.S., Ushio-Fukai M., Malik A. NADPH oxidase dependent signaling in endothelial cells. Role in physiology and pathophysiology. Antioxid. Redox Signal. 2009, 11(4):791-810.
75. Yager J.D., Chen J.Q. Mitochondrial estrogen receptors-new insights into specific functions. Trends Endocrinol. Metab. 2007, 18:89-91.
76. Schafer M., Schafer C., Ewald N., Piper H.M., Noll T. Role of redox signaling in the autonomous proliferative response of endothelial cells to hypoxia. Circ. Res. 2003, 92:1010-1015.
77. Felty Q., Xiong W.C., Sun D., Sarkar S., Singh K.P., Prakash J., Roy D. Estrogen induced mitochondrial reactive oxygen species as signal transducing messengers. Biochemistry 2005, 44:6900-6909.
78. Mattingly K.A., Ivanova M.M., Riggs K.A., Wichramasinghe N.S., Barch M.J., Klinge C.M. Estradiol stimulates transcription of nuclear respiratory factor 1 and increases mitochondrial biogenesis. Mol. Endocrinol. 2008, 22:609-622.
79. Tamir S., Izrael S., Vaya J. The effect of oxidative stress on ER-alpha and ER-beta expression. J. Steroid Biochem. Mol. Biol. 2002, 81:325-332.
80. Mukherjee T.K., Reynolds P.R., Hoidal J.R. Differential effect of estrogen receptor alpha and beta agonists on the receptor for advanced glycation end product expression in human microvascular endothelial cells. Biochim. Biophys. Acta (Mol. Cell Res.) 2005, 1745:300-309.
81. O'Lone R., Knorr K., Jaffe I.Z., Schaffer M.E., Martini Paolo G.V., Karas R.H., Bienkowska J., Mendelsohn M.E., Hansen U. Estrogen receptor alpha and beta mediate distinct pathways of vascular gene expression, including genes involved in mitochondrial electron transport and generation of reactive oxygen species. Mol. Endocrinol. 2007, 21:1281-1296.
82. Zhu X., Smith M.A., Honda K., Aliev G., Moreira P.I., Nunomura A., Casadesus G., Harris P.L., Siedlak S.L., Perry G. Vascular oxidative stress in Alzheimer's disease. J. Neurol. Sci. 2007, 257:240-246.
83. Casadesus G., Smith M.A., Zhu X., Aliev G., Cash A.D., Honda K., Perry G. Alzheimer's disease: evidence for a central pathogenic role of iron mediated reactive oxygen species. J. Alzheimer's Dis. 2004, 6:165-169.
84. Naftolin F., Maclusky N.J., Leranth C.Z., Sakamoto H.S., Garcia-Segura L.M. The effects of estrogens on neuroendocrine tissues. J. Steroid Biochem. 1988, 30:195-207.
85. Huang A.J., Stanbury M.G., Shanabrough M., Horvath T.L., Garcia-Segura L.M. Estrogen, synaptic plasticity and hypothalamic reproductive aging. Exp. Gerontol. 2003, 38:53-59.
86. Schipper H.M. Gomori-positive astrocytes: biological properties and implications for neurologic and neuroendocrine disorders. Glia 1991, 4:365-377.
87. Sur P., Sribnick E.A., Wingrave J.M., Nowak M.W., Ray S.K., Banik N.L. Estrogen attenuates oxidative stress induced apoptosis in C6 glial cells. Brain Res. 2003, 97:178-188.
88. Green P.S., Gordon K., Simpkins J.W. Phenolic A ring requirements for the neuroprotective effects of steroids. J. Steroid Biochem. Mol. Biol. 1997, 63:229-235.
89. Miller C.P., Jirkovsky I., Hayhurst D.A., Adelman S.J. In vivo antioxidant effects of estrogens with a hindered 3-OH function on the copper induced oxidation of low density lipoproteins. Steroids 1996, 61:305-308.
90. Prokai L., Oon S.M., Prokai-Tatrai K., Abbound K.A., Simpkins J.W. Synthesis and biological evaluation of 17-alkoxyestra-1, 35(10)-triens as potential neuroprotectants against oxidative stress. J. Med. Chem. 2001, 44:110-114.
91. Moorsmann B., Behl C. The antioxidant neuroprotective effects of estrogens and phenolic compounds are independent from their estrogenic properties. PNAS (USA) 1999, 96:8867-8872.
92. Simpkins J.W., Rajkumar G., Zhang Y.Q., Simpkins C.E., Greenwald D., Yu C.J., Bopdor N., Day A.L. Estrogens may reduce mortality and ischemic damage caused by middle cerebral artery occlusion in the female rat. J. Neurosurg. 1997, 87:724-730.
93. Biewenga E., Cabell L., Audesirk T. Estradiol and raloxifen protect cultured SN4741 neurons against oxidative stress. Neurosci. Lett. 2005, 373:179-183.
94. Bains J.S., Shaw C.A. Neurodegenerative disorders in humans: the role of glutathione in oxidative stress mediated neuronal death. Brain Res. Rev. 1997, 25:335-358.
95. Green P.S., Perez E.J., Calloway T., Simpkins J.W. Estradiol attenuation of beta-amyloid toxicity: a comparison of MTT and calcein assays. J. Neurocytol. 2000, 29:419-423.
96. Prokai L., Prokai-Tatrai K., Perjesi P., Zharikova A., Simpkins J.W. Quinol based bioreversible metabolic cycle for estrogens in rat liver microsomes. Drug Metab. Dispos. 2003, 31:701-704.
97. Mize A.L., Shapiro R.A., Dorsa D.M. Estrogen receptor mediated neuroprotection from oxidative stress requires activation of the mitogen activated protein kinase pathway. Endocrinology 2003, 144:306-312.
98. Zhao L., Chen S., Brinton R.D. An estrogen replacement therapy containing nine synthetic plant based conjugated estrogens promotes neuronal survival. Exp. Biol. Med. (Maywood) 2003, 228:823-835.
99. Fizptrick J.L., Mize A.L., Wade C.B., Harris J.A., Shapiro R.A., Dorsa D.M. Estrogen mediated neuroprotection against beta-amyloid toxicity requires expression of estrogen receptor alpha and beta and activation of the MAPK pathway. J. Neurochem. 2002, 82:674-682.
100. Marin R., Guerra B., Kang X.L., Fraser J.D., Lopez F.J., Alonso R. Estradiol prevents amyloid-beta peptide induced cell death in a cholinergic cell line via modulation of a classical estrogen receptor. Neuroscience 2003, 121:917-926.
101. Nilson J., Mor G., Naftolin F. Estrogen-regulated developmental neuronal apoptosis is determined by estrogen receptor subtype and the Fas/Fas ligand system. J. Neurobiol. 2000, 43:64-78.
102. Dubal D.B., Zhu H., Yu J., Rau S.W., Shughrue P.J. Estrogen receptor alpha not beta, is critical link is estradiol mediated protection against brain injury. PNAS (USA) 2001, 98:1952-1957.
103. Kim H., Bang O.Y., Jung M.W., Ha S.D., Huh K., Kim S.U., Mook-Jung I. Neuroprotective effects of estrogen against beta-amyloid toxicity are mediated by estrogen receptors in cultured neurone cells. Neurosci. Lett. 2001, 302:58-62.
104. Nuedling S., Karas R.H., Mendelsohn M.E., Mayer R., Vetter H., Grohe C. Activation of estrogen receptor beta is a prerequisite for estrogen dependent upregulation of nitric oxide synthases in neonatal rat cardiac myocytes. FEBS Lett. 2001, 502:103-108.
105. Hayashi T., Yamada K., Esaki T., Kuzuya M., Satake S., Ishikawa T., Hidaka H., Iguchi A. Estrogen increases endothelial nitric oxide by a receptor mediated system. Biochem. Biophys. Res. Commun. 1995, 214:847-855.
106. Alexaki V.I., Charalampopoulos I., Kampa M., Vassalou H., Gravanis A., Castanas E. Estrogen exerts neuroprotective effects via membrane estrogen receptors and rapid Akt/NOS activation. FASEB J. 2004, 18:1594-1596.
107. Wen Y., Sarkar S.N., Simpkins J.W. nNOS is involved in estrogen mediated neuroprotection in neuroblastoma cells. NeuroReport 2004, 15:1515-1518.
108. Wyckoff M., Chambliss K., Mineo C., Mendeksohn M., Mumby S., Shaul P. Plasma membrane estrogen receptors are coupled to endothelial nitric oxide synthases through G alpha. J. Biol. Chem. 2001, 276:27071-27076.
109. Rao A., Ziegler Y., McLeod I., Yates J., Nardulli A. Thioredoxin and thioredxin reductase influence estrogen receptor alpha mediated gene expression in human breast cancer cells. J. Mol. Endocrinol. 2009, 43(6):251-261.
110. Lee Y.S., Andoh T., Murphy D.L., Chiueh C.C. 17-beta estradiol activates ICI182780 sensitive estrogen receptors and cyclic GMP dependent thioredoxin expression for neuroprotection. FASEB J. 2003, 17:947-951.
111. Cheng G., Li Y., Omoto K., Yang Y., Berg T., Nord M., Gustaffson J.A. Differential regulation of estrogen receptor alpha and beta in primate mammary gland. J. Clin. Endocrinol. Metab. 2005, 90:435-444.
112. Chang E.C., Charn T.H., Park S.H., Helferich W.G., Komm B., Katzenellenbogen J.A., Katzenellenbogen B.S. Estrogen receptors α and β as determinants of gene expression: influence of ligand, dose, and chromatin binding. Mol. Endocrinol. 2008, 22:1032-1043.
113. Riggins R.B., Lan J.P., Zhu Y., Klimach U., Zwart A., Cavalli L.R., Haddad B.R., Chen L., Gong T., Xuan J., Ethier S.P., Clarke R. ERRgamma mediates tamoxifen resistance in novel models of invasive lobular breast cancer. Cancer Res. 2008, 68:8908-8917.